| Suspended | CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome NCT05617625 | Guenther Koehne | Phase 2 |
| Not Yet Recruiting | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications NCT07240649 | Jay C. Buckey Jr. | Phase 4 |
| Not Yet Recruiting | Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD NCT07364617 | Chang Gung Memorial Hospital | Phase 2 |
| Not Yet Recruiting | HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR NCT07210242 | Ting YANG | — |
| Recruiting | Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD NCT07184853 | First Affiliated Hospital of Zhejiang University | N/A |
| Recruiting | Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Gra NCT06824103 | Novartis Pharmaceuticals | Phase 4 |
| Withdrawn | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant NCT05968170 | Neena Kapoor, M.D. | N/A |
| Recruiting | A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant NCT07006506 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Vitamin A Supplementation in Allogeneic Stem Cell Transplantation. NCT06450925 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Recruiting | Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation NCT06649201 | Case Comprehensive Cancer Center | — |
| Recruiting | A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention NCT06681922 | Northwell Health | Phase 1 / Phase 2 |
| Recruiting | Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD NCT06568328 | Fujian Medical University | Phase 1 |
| Recruiting | Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine NCT06008808 | Washington University School of Medicine | Phase 1 |
| Unknown | Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD NCT06133192 | Central Hospital, Nancy, France | Phase 2 |
| Active Not Recruiting | Horizons Chronic Graft-Versus-Host-Disease Study NCT06160986 | University of Miami | N/A |
| Recruiting | Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain. NCT07365696 | Karolinska University Hospital | — |
| Completed | Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients NCT06080490 | University of Pisa | — |
| Unknown | Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg NCT05780554 | Centro de Hematología y Medicina Interna | N/A |
| Recruiting | Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease NCT05531786 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD NCT05621759 | NYU Langone Health | Phase 2 |
| Suspended | Optoacoustic Detection of Inflammation Using MSOT Device NCT05333978 | University of Oklahoma | N/A |
| Completed | Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Pr NCT05718674 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy NCT05333367 | Centre Hospitalier Universitaire de Besancon | N/A |
| Recruiting | Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial NCT05236062 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis NCT04380740 | Boston Children's Hospital | Phase 2 |
| Active Not Recruiting | GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG NCT05153226 | DKMS gemeinnützige GmbH | Phase 3 |
| Active Not Recruiting | A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to NCT05132166 | University Health Network, Toronto | Phase 2 |
| Completed | Evaluation of the Impact of Reduced Immunosuppression NCT05238155 | Methodist Health System | — |
| Unknown | Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells NCT05167188 | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | — |
| Active Not Recruiting | IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms NCT05111834 | University Hospital Heidelberg | N/A |
| Withdrawn | Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes NCT04728646 | Massachusetts Eye and Ear Infirmary | Phase 4 |
| Unknown | Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease NCT05152160 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases NCT04922736 | University of Utah | N/A |
| Recruiting | oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort NCT05170347 | The University of Hong Kong | — |
| Completed | The Influence of Extracorporeal Photopheresis on Skin Sclerosis NCT04752397 | Charite University, Berlin, Germany | — |
| Completed | Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT NCT04738981 | Peking University People's Hospital | Phase 3 |
| Recruiting | IS-free Treg HaploHCT NCT04678401 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide NCT04622956 | University of Sao Paulo General Hospital | Phase 1 / Phase 2 |
| Unknown | Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease NCT04448587 | Rabin Medical Center | Phase 2 |
| Unknown | Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT NCT06143501 | The First Affiliated Hospital of Soochow University | — |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Active Not Recruiting | Multidisciplinary Intervention In Chronic GVHD NCT04479995 | Massachusetts General Hospital | N/A |
| Completed | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Di NCT03774082 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD NCT04227938 | Alpine Immune Sciences, Inc. | Phase 1 |
| Completed | Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transpl NCT04131738 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Terminated | Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease NCT04070781 | Columbia University | Phase 1 |
| Recruiting | A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant NCT04337515 | Christopher Dvorak | N/A |
| Terminated | Ibrutinib and Rituxan for Chronic GVHD NCT04235036 | Northside Hospital, Inc. | Phase 2 |
| Completed | RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem NCT04014790 | Regimmune Corporation | Phase 2 |
| Unknown | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation NCT03836690 | University College, London | Phase 1 |
| Recruiting | Pediatric cGVHD Symptom Scale NCT04044365 | National Cancer Institute (NCI) | — |
| Terminated | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease NCT03591874 | Ocugen | Phase 3 |
| Completed | Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentica NCT04687982 | Istituto Clinico Humanitas | N/A |
| Completed | Cellular Stress Reactions During Graft-versus-host Disease NCT04558788 | University of Freiburg | — |
| Completed | Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic NCT03434704 | Ciceri Fabio | Phase 2 |
| Completed | Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transpla NCT03207958 | Washington University School of Medicine | Phase 1 |
| Completed | Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT NCT03575767 | Affiliated Hospital to Academy of Military Medical Sciences | — |
| Completed | A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refra NCT03474679 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | The Safety and Tolerability of Pirfenidone for BOS After HCT NCT03315741 | Stanford University | Phase 1 |
| Unknown | Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders NCT03731624 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | — |
| Unknown | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases NCT03340155 | Medical University of Graz | N/A |
| Unknown | Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoie NCT03136757 | Centre Hospitalier Universitaire, Amiens | — |
| Completed | Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF NCT05018754 | University of Rome Tor Vergata | — |
| Terminated | Ruxolitinib In GvHD NCT02396628 | Prof. Dr. Nikolas von Bubnoff | Phase 2 |
| Completed | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression NCT02891603 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. NCT03229200 | Pharmacyclics Switzerland GmbH | Phase 4 |
| Terminated | A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation NCT02737306 | CytoDyn, Inc. | Phase 2 |
| Enrolling By Invitation | Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) NCT03369353 | Boston Children's Hospital | — |
| Completed | Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT NCT02876679 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Topical Vitamin D in Acute Graft Versus Host Disease of the Skin NCT03093805 | Children's Hospital Medical Center, Cincinnati | N/A |
| Completed | A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease NCT02923375 | Cynata Therapeutics Limited | Phase 1 |
| Terminated | 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients NCT03546556 | UNC Lineberger Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease NCT02172924 | Karolinska Institutet | Phase 1 / Phase 2 |
| Completed | Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation NCT02867384 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host NCT02841995 | Kadmon, a Sanofi Company | Phase 2 |
| Completed | Ruxolitinib for Steroid-refractory GVHD NCT02997280 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Unknown | Graft-versus-host Disease Associated Myelosuppression NCT02829216 | Technische Universität Dresden | — |
| Completed | Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD NCT02525029 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transpl NCT02683525 | Sherif S. Farag | Phase 2 |
| Terminated | Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD NCT02411084 | Adienne SA | Phase 3 |
| Unknown | Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVH NCT00517907 | Hadassah Medical Organization | Phase 1 |
| Unknown | The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantati NCT02506231 | Rabin Medical Center | Phase 2 / Phase 3 |
| Unknown | Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease NCT02770430 | Hospital de Clinicas de Porto Alegre | Phase 2 |
| Unknown | Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease NCT02478424 | Rabin Medical Center | Phase 2 |
| Completed | Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT NCT02398708 | University of Florida | — |
| Completed | Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat NCT02409134 | Sung Choi, M.D. | — |
| Unknown | A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease NCT02385019 | Instituto de Medicina Molecular João Lobo Antunes | Phase 1 / Phase 2 |
| Completed | Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantatio NCT02945176 | Implandata Ophthalmic Products GmbH | N/A |
| Terminated | Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Th NCT02322190 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Trans NCT01790568 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantati NCT02337595 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Unknown | Toward Immune Biomarkers for Tolerance and GvHD in Humans NCT02319226 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disea NCT02105766 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | CEC Count Changes to Support GvHD Diagnosis. NCT02064972 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Completed | Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD NCT02027805 | Xenikos | Phase 1 / Phase 2 |
| Terminated | Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Vers NCT01950507 | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Terminated | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT NCT03963024 | IRCCS San Raffaele | Phase 1 |
| Completed | Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation NCT01665677 | Mehdi Hamadani | Phase 2 |
| Terminated | Preemptive Therapy of GVHD NCT01994824 | University of Calgary | Phase 2 |
| Terminated | A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chroni NCT01972438 | National Eye Institute (NEI) | Phase 2 |
| Terminated | Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) NCT01940796 | Massachusetts General Hospital | Phase 1 |
| Completed | A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease NCT01700036 | University of Michigan Rogel Cancer Center | Phase 2 |
| Active Not Recruiting | Chronic GVHD Response Measures Validation NCT01902576 | Fred Hutchinson Cancer Center | — |
| Completed | Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research NCT01851382 | National Cancer Institute (NCI) | — |
| Completed | Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Ho NCT01713400 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Abatacept as GVHD Prophylaxis Phase 2 NCT01743131 | Boston Children's Hospital | Phase 2 |
| Completed | Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menar NCT01512498 | Hadassah Medical Organization | — |
| Completed | Pomalidomide for Chronic Graft-versus-Host Disease NCT01688466 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Brentuximab Vedotin for Steroid Refractory GvHD NCT01596218 | Massachusetts General Hospital | Phase 1 |
| Completed | Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease NCT01788501 | Seoul National University Hospital | Phase 2 / Phase 3 |
| Completed | Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation NCT01206309 | Fred Hutchinson Cancer Center | — |
| Completed | Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye NCT01393132 | Michigan Cornea Consultants, PC | Phase 2 |
| Terminated | Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans NCT01327625 | Asan Medical Center | N/A |
| Completed | Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients fo NCT01287078 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Unknown | Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study NCT02172937 | Karolinska Institutet | Phase 1 / Phase 2 |
| Completed | Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versu NCT01318330 | HomeoTherapy Co., Ltd | Phase 1 |
| Completed | Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease NCT01221766 | Dana-Farber Cancer Institute | — |
| Completed | Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantati NCT01175148 | West Virginia University | Phase 2 |
| Completed | Cord Blood Serum in the Treatment of Ocular Surface Diseases NCT01234623 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Terminated | Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients NCT01282879 | Samsung Medical Center | Phase 4 |
| Completed | Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease NCT01042509 | Hospital Universitario Dr. Jose E. Gonzalez | N/A |
| Unknown | Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD) NCT01764100 | Ettore Biagi, MD | Phase 1 |
| Completed | CC-4047 (Pomalidomide) for Graft vs. Host Disease NCT00770757 | Washington University School of Medicine | Phase 2 |
| Completed | Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplan NCT00810602 | Pavan Reddy, MD | Phase 1 / Phase 2 |
| Completed | A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease NCT00760981 | David Miklos | Phase 1 |
| Completed | Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus NCT01699412 | Grupo de Estudos Multicentricos em Onco-Hematologia | Phase 3 |
| Completed | A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Al NCT00670423 | Jennifer E. Schwartz | Phase 1 |
| Completed | Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease NCT00632658 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Terminated | Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced NCT00548717 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Rituximab for GVHD NCT00578591 | Baylor College of Medicine | Phase 2 |
| Unknown | Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease NCT00314483 | Christian Medical College, Vellore, India | Phase 1 / Phase 2 |
| Terminated | Thymoglobulin (ATG) Dose Finding Study NCT00409695 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease NCT00391170 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Myfortic - Treatment for Extensive cGvHD NCT00298324 | European Society for Blood and Marrow Transplantation | Phase 3 |
| Completed | A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease NCT00350545 | Stanford University | N/A |
| Completed | Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVH NCT00574470 | University of Iowa | Phase 4 |
| Completed | Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease ( NCT00248365 | Kiadis Pharma | Phase 1 / Phase 2 |
| Completed | Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease NCT00388362 | Stanford University | Phase 2 |
| Terminated | Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Ev NCT00117702 | Technische Universität Dresden | Phase 2 / Phase 3 |
| Completed | Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) NCT00224874 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients NCT00195429 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Unknown | Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation NCT00207792 | Centre National de Greffe de Moelle Osseuse | Phase 3 |
| Completed | Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD NCT00136903 | Mesoblast, Inc. | Phase 2 |
| Recruiting | Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants NCT00106925 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation NCT00130754 | Hadassah Medical Organization | Phase 3 |
| Completed | Study Evaluating Sirolimus in Kidney Transplant Recipients. NCT00167947 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Study Evaluating Sirolimus in Kidney Transplant Recipients NCT00195273 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Cyclosporine Implant for Ocular Graft-Versus-Host Disease NCT00102583 | National Eye Institute (NEI) | Phase 1 |
| Completed | A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension NCT00189748 | Astellas Pharma Inc | Phase 2 |
| Unknown | Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation NCT00563108 | Hospital Authority, Hong Kong | N/A |
| Completed | Study Evaluating Sirolimus in Kidney Transplant Recipients in India NCT00195481 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Takin NCT00195468 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease NCT00136396 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children NCT00144430 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 |
| Unknown | Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Trans NCT00563589 | Hospital Authority, Hong Kong | N/A |
| Completed | Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant NCT00179049 | Vanderbilt University | — |
| Completed | Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant NCT00179075 | Vanderbilt University | — |
| Completed | Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Tr NCT00655343 | Neovii Biotech | Phase 3 |
| Completed | Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease NCT00048789 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease NCT00032292 | Facet Biotech | Phase 1 / Phase 2 |
| Unknown | Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease NCT00032279 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Blood and Marrow Transplant Clinical Research Network NCT00023530 | National Heart, Lung, and Blood Institute (NHLBI) | N/A |
| Completed | Keratinocyte Growth Factor to Prevent Acute GVHD NCT00031148 | FDA Office of Orphan Products Development | Phase 1 / Phase 2 |
| Completed | Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells NCT00023491 | National Institute of Dental and Craniofacial Research (NIDCR) | — |
| Completed | Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointest NCT00233896 | Enteron Pharmaceuticals | Phase 3 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following NCT00128739 | Rafa Laboratories | Phase 3 |
| Completed | Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD) NCT00146978 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia NCT00001144 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Vers NCT00035880 | Abgenix | Phase 2 / Phase 3 |
| Completed | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants NCT00001830 | National Cancer Institute (NCI) | Phase 1 |
| Completed | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers NCT00001873 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease NCT00001872 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease NCT00186667 | Stanford University | Phase 2 |
| Completed | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malig NCT00001748 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Ad NCT00001637 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia NCT00001623 | National Heart, Lung, and Blood Institute (NHLBI) | N/A |
| Completed | Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient NCT00001561 | National Cancer Institute (NCI) | Phase 3 |
| Completed | T-Cell Depletion in Unrelated Donor Marrow Transplantation NCT00000591 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients NCT00044720 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| No Longer Available | Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After NCT03172455 | Impatients N.V. trading as myTomorrows | — |
| Completed | Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients NCT00037531 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Unknown | High Dose Chemotherapy and Autologous Transplant for Breast Cancer NCT00186641 | Stanford University | Phase 2 |
| Completed | A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Reci NCT00189761 | Astellas Pharma Inc | Phase 2 |
| No Longer Available | Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD NCT00759018 | Mesoblast, Inc. | — |
| Completed | GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Hos NCT00228839 | Emory University | Phase 1 |